CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients.

Jiaxuan ChenShuang LouHaitao ChenBin ZhouJian SunJinlin HouDe-Ke Jiang

Published in: Journal of clinical and translational hepatology (2022)

_rs28371597 is a promising biomarker for predicting CHB patients' responsiveness to PegIFNα therapy. The updated PGS may be used for optimizing CHB treatment.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
hepatitis b virus
prognostic factors
stem cells
dendritic cells
cell therapy